Navigation Links
Select Medical Holdings Corporation Announces Exercise of Underwriters' Option to Purchase Additional Shares
Date:10/24/2009

MECHANICSBURG, Pa., Oct. 23 /PRNewswire-FirstCall/ -- Select Medical Holdings Corporation ("Select") (NYSE: SEM), the parent of Select Medical Corporation, today announced that it had received notice of the exercise of the underwriters' over-allotment option to purchase an additional 3,602,700 shares of Select's common stock at a price per share of $10.00, which is expected to close on October 28, 2009, subject to customary closing conditions. The over-allotment option was granted in connection with Select's initial public offering of 30,000,000 shares, which closed on September 30, 2009.

Total additional net proceeds to Select from the exercise of the over-allotment option are expected to be approximately $33.9 million. Select intends to use the net proceeds from the exercise of the over-allotment option to repay indebtedness. Any remaining net proceeds will be used for general corporate purposes.

Goldman, Sachs & Co., Morgan Stanley & Co. Incorporated, BofA Merrill Lynch and J.P. Morgan Securities Inc. acted as joint book-runners for the offering.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. A copy of the final prospectus related to the offering may be obtained from Goldman, Sachs & Co., Attention: Prospectus Department, 85 Broad St., New York, NY 10004 or by faxing (212) 902-9316 or calling toll-free 1-866-471-2526 or emailing at prospectus - ny@ny.email.gs.com; or Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, New York 10014 (email address: prospectus@morganstan
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
2. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
3. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
4. Sharp HealthCare Selects MEDais Pinpoint Review to Prevent Readmissions
5. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
6. Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution
7. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
8. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
9. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
10. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
11. Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... post-marketing commitment and submissions of data to regulatory ... Cancer Risk Characterization Study , a large (n= ... four European countries, for pioglitazone containing medicines, including ... of follow-up. Findings demonstrate that there is no ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... survival studies that were conducted in Dr. William Scheld,s lab at ... treated with an siRNA against Senesco,s Factor 5A gene had a ... mice that received no treatment or a control siRNA.A total of ...
... speculation over what course the Swine Flu epidemic will ... ) last week analyzed the most recent peptide ... of the H1N1 virus will increase markedly, while its ... company,s quantitative analysis of the most recent sequence data ...
Cached Medicine Technology:Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 2
(Date:7/30/2015)... ... 2015 , ... " DevExpress ” was featured on NewsWatch ... medium, and large businesses making an impact in their industry. Susan Bridges, a ... with viewers how DevExpress has provided software development tools that have helped app ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never ... provide comfort to patients as well as visiting friends and family during these critical ... stations. , The stations - powered by ChargeItSpot , a Philadelphia-based startup that ...
(Date:7/30/2015)... ... 30, 2015 , ... OncLive®’s extensive roster of ... Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that promote ... marketing groups will help spread the news about the center’s leading-edge cancer research, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a ... That Increases Training Capability , World renown body weight trainer, Paul Ziachik, ... ), that dramatically increases a person’s training capability. , The American College of ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... and UNAIDS today issued new guidance on informed, voluntary ... with a view to significantly increasing access to needed ... ,The new guidance focuses on provider-initiated HIV ... in health facilities. ,Today, approximately 80 ...
... women, half of whom had breast cancer , has revealed ... risk of breast cancer. ,Douglas Easton at the ... was observed in one out of six women during the ... gene variant, in the gene called fibroblast growth factor receptor ...
... two certainties in life: "death and taxes." Joseph Dello Russo, ... for wearing reading glasses after forty, a condition doctors ... with a team of researches who in the past have ... are now hard at work with what may be a ...
... the University of Wisconsin-Madison have identified dozens of clues ... ,The researchers identified nearly 40 genes that, ... the parasite from forming an infection in the brains ... of promising targets for developing drugs that could block ...
... India. But they could also prove a huge embarrassment for ... Thirumurthy Nakka Boomaiah , 35 and hailing from Chennai, in ... has been sentenced to 69 days in prison in US ... and assaulting flight attendants. But he has already spent the ...
... patients will have a new -- virtually pain free ... Mercy Health System (SJMHS) announced today it will begin ... on Wednesday, June 6th. ,This advanced radiosurgery ... including previously inoperable tumors, with astounding accuracy and with ...
Cached Medicine News:Health News:WHO, UNAIDS Issue New Guidance on HIV Testing and Counseling 2Health News:Researchers Identify the Gene Mutation That Raises Breast Cancer Risk 2Health News:Cure for Reading Glasses? 2Health News:Mutant Parasites, Unable to Infect Hosts, Highlight Virulence Genes 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2
...
... System* was designed to provide ... range of prosthesis for a ... With the addition of the ... a more complete range of ...
...
... The only shoulder prosthesis with ... experience in thousands of patients. Ideal ... resulting in 3 or 4 part ... greater than 50%, head-splitting fractures, disabling ...
Medicine Products: